PetVivo Holdings, Inc.

PetVivo Holdings, Inc. is an emerging biomedical device company that manufactures, commercializes, and licenses innovative medical devices and therapeutics for animals. The company has a pipeline of seventeen products for the treatment of animals and humans. Its biomaterials, products, production processes, and methods of use are protected by a portfolio of ten issued patents (six U.S. patents and four foreign patents), two U.S. patent applications, and six proprietary trade secrets. PetVivo began commercializing its lead product, Spryng® with OsteoCushion® Technology, in the second quarter of its fiscal year ended March 31, 2022. Spryng® is a veterinarian-administered, intraarticular injection used for managing lameness and other joint conditions like osteoarthritis in dogs and horses. In August 2021, the company received net proceeds of approximately $9.7 million from a public offering of 2.5 million units at $4.50 per unit. Each unit included one share of common stock and one warrant to purchase one share of common stock at an exercise price of $5.625 per share. The common stock and warrants were transferable separately upon issuance. The company's common stock and warrants were registered under Section 12(b) of the Exchange Act and initially traded on The Nasdaq Capital Market, LLC under symbols "PETV" and "PETVW." Currently, the company trades on the OTC Markets Group, under the OTCQX Best Market tier, using the same symbols "PETV" and "PETVW." PetVivo Holdings, Inc. was incorporated in March 2009 under Nevada law and operates as one segment from its corporate headquarters in Edina, Minnesota. The company primarily focuses on commercializing and licensing products in the veterinary market to treat and manage afflictions in companion animals such as cats, dogs, and horses.